Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s CEO Dr James Garner tells Proactive they've officially enrolled the first patient in its investigational cancer therapy trial. The oncology-focused drug development company licensed the cancer therapy, known as EVT801, from German biotech Evotec AG in April 2021. The phase one study will focus primarily on understanding the safety, tolerability and pharmacokinetics of EVT801 across a range of doses.
Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial
